)
Visual
test
Gain Therapeutics
Gain Therapeutics (GANX) investor relations material
Gain Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Mar, 2026
Executive summary
Advanced lead candidate GT-02287 for Parkinson's disease, with promising Phase 1b data showing disease-modifying potential and stable MDS-UPDRS scores over 150 days of treatment.
Completed enrollment in Phase 1b nine-month extension; 14 of 16 participants completed 5 months of dosing as of March 2026.
Presented new preclinical and clinical data at major scientific conferences, supporting the mechanism and efficacy of GT-02287.
GT-04686, a novel GCase allosteric modulator, is ready for IND-enabling studies.
Financial highlights
Research and development expenses decreased to $10.2M for 2025 from $10.8M in 2024, mainly due to pipeline cost optimization.
General and administrative expenses fell to $8.5M from $9.6M, driven by lower stock-based compensation and legal fees.
Net loss for 2025 was $20.2M ($0.61 per share), compared to $20.4M ($0.89 per share) in 2024.
Cash, cash equivalents, and marketable securities totaled $20.8M at year-end 2025, up from $10.4M at year-end 2024.
Outlook and guidance
IND submission clearance for GT-02287 expected in 2Q26, enabling Phase 2 clinical development in the US.
Phase 2 clinical trial for GT-02287 in Parkinson's disease anticipated to begin in 3Q26.
Results from the Phase 1b clinical study expected in 4Q26.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gain Therapeutics
- Disease-modifying Parkinson's therapy advances to phase II with strong biomarker support.GANX
The 38th Annual Roth Conference24 Mar 2026 - GT-02287 demonstrates disease-modifying potential in Parkinson's with strong clinical and biomarker data.GANXCorporate presentation16 Mar 2026
- Raised $11M to advance GT-02287 for Parkinson's, with key trial data and leadership changes.GANXStatus Update3 Feb 2026
- GT-02287 moves to Phase 1b for Parkinson's, targeting disease modification with broad patient inclusion.GANXMaxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026
- GT-02287 reduced CSF glucosylsphingosine by 81% and improved UPDRS scores in Parkinson's patients.GANXStudy Update6 Jan 2026
- GT-02287 shows early safety and clinical promise in Parkinson's, with key data due year-end.GANXStudy Result29 Dec 2025
- Shelf registration for up to $100M supports pipeline growth and clinical trials in CNS and rare diseases.GANXRegistration Filing16 Dec 2025
- Up to $100M in securities may be offered to advance a promising Parkinson's therapy and pipeline.GANXRegistration Filing16 Dec 2025
- Annual meeting to vote on directors, auditor, share increase, and governance matters.GANXProxy Filing2 Dec 2025
Next Gain Therapeutics earnings date
Q1 202613 May, 2026
Gain Therapeutics
Next Gain Therapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage